Concomitant determination of hematological indices supported the application of the albumin-bilirubin score in non-malignant liver diseases

doi:10.4254/wjh.v16.i9.1308

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (362)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

314

Sum=327

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=25

Sep 27, 2024 (publication date) through Oct 4, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Hepatol. Sep 27, 2024; 16(9): 1308-1311
Published online Sep 27, 2024. doi: 10.4254/wjh.v16.i9.1308

Concomitant determination of hematological indices supported the application of the albumin-bilirubin score in non-malignant liver diseases

Marwan S M Al-Nimer

Marwan S M Al-Nimer, Department of Pharmacology, College of Medicine, University of Diyala, Baqubah 32001, Iraq

Author contributions: Al-Nimer MSM completely wrote the letter to the editor.

Conflict-of-interest statement: The author declares no conflict-of-interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Marwan S M Al-Nimer, MBChB, MD, PhD, Professor Emerita, Department of Pharmacology, College of Medicine, University of Diyala, University Street, Baqubah 32001, Iraq. marwanalnimer@yahoo.com

Received: March 12, 2024
Revised: August 12, 2024
Accepted: August 26, 2024
Published online: September 27, 2024
Processing time: 194 Days and 20.5 Hours

Core Tip

Core Tip: Albumin-bilirubin (ALBI) score is a prognostic biomarker in hepatocellular carcinoma and non-malignant liver diseases, as a higher level in the pretreatment state is associated with poor prognosis. Hematological ratios, notably the platelet-lymphocyte ratio (PLR) and platelet-hemoglobin ratio (PHR) are also useful prognostic biomarkers in hepatic pathological conditions. Concurrent measurement of PLR and ALBI score, or ALBI score and PHR, supports the prediction value of the ALBI score and makes sense to establish a cutoff value for non-malignant conditions.